tbuckley/cabot-search huggingface dataset:
Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors
Authors: M Gabbianelli, E Pelosi, E Montesoro, M Valtieri, L Luchetti, P Samoggia, L Vitelli, T Barberi, U Testa, S Lyman
Journal: Blood (1995)
TCT-793 The Elephant in the Room: the Increased Incidence of Neurological Deficits with Carotid Endarterectomy Versus Protected Carotid Stenting in Randomized Controlled Trials
Authors: Alexandre M. Benjo, Yamini Ayakannu, Christopher White, Sayf Altabaqchali, Cody Williams, Georges EL-Hayek, Rajan Patel
Journal: Journal of the American College of Cardiology (2015)
Use of oral contraceptives by adolescents in Finland [letter]
Authors: Fleming C, Coles R, Cahill Dj
Journal: BMJ (1993)

Finland is to be congratulated on having reduced pregnancy rates during the 1980s.  We are concerned however at Arja H Rimpela and colleagues implication that increased use of oral contraceptives (OCs) could be related to a coincident rise in venous thromboembolism.  Firstly there is no evidence that the cases of thromboembolism quoted occurred in users of OCs.  Secondly if hospital discharges of patients after pulmonary embolism cerebrovascular diseases and deep vein thrombosis did not show a rising trend it is implausible that the rise in all cases in ICD categories 451 and 453 can be attributed to sue of OCs.  Lastly there is no mention of other risk factors for thromboembolism although the number of teenage smokers in Finland rose significantly during the 1980s.  Unsubstantiated emphasis on the negative aspects of use of OCs must be avoided if we are to reduce the incidence of unwanted teenage pregnancies in Britain.  (full text) (2 references cited in original document)
Abstract 197: Determining the Potential Role of cTnT Isoform Switching In the Development of Early Childhood Tropomyosin-Linked DCM
Authors: Melissa Lynn, Lauren Tal-Grinspan, J.P. Jin, Jil Tardiff
Journal: Circulation Research (2014)

An oft-noted component of sarcomeric HCM and DCM is the observation that patients within families, carrying the same primary mutation, often exhibit significant phenotypic variability. This lack of a distinct link between genotype and phenotype has greatly complicated clinical management. In a recent study of two large unrelated multigenerational families carrying the tropomyosin (Tm) mutation Asp230Asn (D230N), a striking “bimodal” distribution of severity was observed. In these families, many children (&lt;1 year) with the mutation presented with a severe form of DCM that led to sudden, often fatal congestive heart failure, while adults developed a mild to moderate DCM in mid-life. Of note, children who survived the initial presentation often recovered significant systolic function in adolescence and young adulthood. Therefore, to better understand the mechanism of this “bimodal” phenotype, we began to investigate the potential modulating role of isoform switching by other sarcomeric components. We hypothesize that the age-dependent remodeling seen in children with D230N Tm is a result of temporal isoform switches involving a closely linked Tm binding partner cardiac Troponin T (cTnT). Initial biophysical studies (circular dichroism and regulated in vitro motility, R-IVM) show that while D230N does not alter Tm’s thermal stability it does have a profound impact on myofilament activation. Both maximal velocity of filament sliding and calcium sensitivity were decreased. Furthermore, an additive decrease was observed in these parameters for R-IVM solutions containing cTnT 1 (fetal)+D230N Tm filaments as compared to cTnT 3 (adult)+D230N. Preliminary in vivo studies utilizing our novel double transgenic Tm-D230N x cTnT 1 mice show profound changes in wall thickness and chamber dilation, as compared to age-matched non-transgenic mice and D230N Tm mice. Further studies aim to model the “bimodal” clinical phenotype seen in families with D230N Tm and assess the potential for disease reversibility using a cardiac specific inducible cTnT 1 transgenic mouse model. Our goal is to use a translational approach to better understand the mechanism by which primary mutations lead to distinct clinical phenotypes in order to improve clinical management.
Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): Results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Authors: B. Kong, M. Biakhov, J. L. Kelley, J. Nunez, C. Lebedinsky, T. V. Parekh, J. B. Vermorken
Journal: Journal of Clinical Oncology (2010)

e15529 Background: OVA-301 was an open-label, multicenter, randomized phase III study comparing Tr+PLD to PLD alone in 672 patients (pts) with ROC. The combination of Tr+PLD demonstrated significantly improved progression free survival and response rates, manageable noncumulative toxicity, fewer PLD-associated adverse events and no adverse effect on patient-reported outcome data (Monk, Ann Oncol. 2008). We studied the impact of the combination of Tr+PLD on TRE. Methods: TRE present at study entry and end of treatment were compared. These included analgesic use including narcotics, weight gain or loss, increase or decrease of ascites or pleural fluid and abdominal pain. Results: Among the pts with pleural fluid at baseline 11 of 28 (39%) in the Tr+ PLD arm had complete resolution compared with 4 of 27 (15 %) in the PLD arm. Resolution usually occurred over 5 cycles in both arm. Among the pts with evaluable disease who had resolution of pleural fluid, 4/7 (57%) in Tr+PLD and 1/4 (25%) in PLD alone arm had CR/PR by independent radiologist. Thirty percent of pts in the Tr+ PLD arm compared with 27% in the PLD arm showed resolution of ascites. The new onset of ascities was observed in 5% of pts in the Tr+ PLD arm compared with 8% in the PLD arm. The incidence of grade 3-4 AEs related to abdominal pain was 1% in the Tr+ PLD arm compared with 5% in the PLD arm. No other differences were observed based on the clinical parameters that were examined. Conclusions: Consistent with the findings from OVA-301, Tr+PLD results in reduced incidence of TRE compared with the PLD alone in patients with relapsed ovarian cancer. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson, PharmaMar Johnson & Johnson, Zeltia Johnson & Johnson
Deficiency Of JAGN1 Causes Severe Congenital Neutropenia Associated With Defective Secretory Pathway and Aberrant Myeloid Cell Homeostasis
Authors: Kaan Boztug, Päivi M Järvinen, Elisabeth Salzer, Tomas Racek, Sebastian Mönch, Wojciech Garncarz, E. Michael Gertz, Alejandro A. Schäffer, Aristotelis Antonopoulos, Stuart Haslam, Lena Ziesenitz, Jacek Puchalka, Jana Diestelhorst, Giridharan Appaswamy, Brigitte Lescoeur, Roberto Giambruno, Johannes Bigenzahn, Ulrich Elling, Dietmar Pfeifer, Karl Welte, Gudrun Brandes, Roya Sherkat, Jutte Van der Werff Ten Bosch, Nima Rezaei, Amos Etzioni, Christine Bellanne-Chantelot, Giulio Superti-Furga, Keiryn L Bennett, Julia von Blume, Anne Dell, Jean Donadieu, Christoph Klein
Journal: Blood (2013)
Update: Acquired Immunodeficiency Syndrome (AIDS)—Worldwide
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC).
Authors: D. Bianchini
Journal: Journal of Clinical Oncology (2010)

4672 Background: AA is a potent inhibitor of CYP17 with antitumor activity in CRPC. The long term safety and tolerability of AA was evaluated. Methods: Patients (pt) receiving AA with or without steroids for >6 months on trials at the Royal Marsden Hospital, enrolled on trials between December 2005 and December 2007, were evaluated. Late toxicities were graded according to CTCAE v3.0. Results: Overall, 102 pt were treated; 70 pt (median age: 72y; ECOG PS 0-2) received AA >6 months (Range: 6 - 51+ cycles), 40 pt > 1 year, 20 > 2 years and 5 pt > 3 years. AA was well tolerated. The commonest early toxicities were hypokalemia and hypertension which were easily managed with eplerenone (50-200 mg/day) or steroids. Late cardiovascular events were uncommon and reported in 3/70 pt. The first pt presented with dyspnea after 8 months of AA treatment having previously received 10 courses of mitoxantrone (total dose of 242 mg). He had a past history of MI, cerebrovascular disease, hypertension and a deep venous thrombosis. The second pt had a MI after just 2 week of AA; an angiogram revealed multi-vessel coronary artery stenosis; stenting was successfully performed. He recovered fully and continued on AA for 34 months. The final pt had a history of hypertension, diabetes and left ventricular dysfunction prior to AA therapy; after 17 months on AA and dexamethasone (0.5mg/day) he developed rapid onset dyspnea and oedema and died rapidly of a presumed PE. Corticosteroid toxicity included: hyperglycemia (67.1%), weight gain (G1/2: 25%) and avascular necrosis (1 patients, 1.4%). Finally, pre- and post-AA median cholesterol levels were 4 and 5 mmol/L, and pre- and post-AA median triglyceride levels were 1 and 1.5 mmol/L, respectively. Conclusions: Delayed toxicity following AA treatment was uncommon. AA was safely administered for long periods without concurrent corticosteroids. Further follow-up of delayed toxicity is required. No significant financial relationships to disclose.
Polyinosinic-Polycytidylic Acid in Two-Stage Skin Carcinogenesis. Effect on Epidermal Growth Parameters and Interferon Induction in Treated Mice
Authors: Kjell Elgjo, Miklos Degré
Journal: JNCI Journal of the National Cancer Institute (1973)

Repeated intraperitoneal administration of synthetic double-stranded RNA polyinosinicpolycytidylic acid (poly I:C) inhibited two-stage skin carcinogenesis in mice. Poly I:C treatment during the whole experimental period reduced the tumor yield, mortality, and latency period. The tumor yield and mortality were decreased even when poly I:C administration was started at the time of appearance of the first tumor. InterFeron production after a single dose of poly I:C was not influenced by repeated topical applications of 3-methylcholanthrene or by previous treatment with poly I:C. A single small dose of poly I:C had no effect on normal epidermal DNA synthesis or mitotic rate, but inhibited the incorporation of tritiated thymidine into DNA of hyperplastic mouse epidermis. The relationship of this inhibition to the antitumorigenic effect of poly I:C is discussed.
Abstract 17133: Cardiac Rehabilitation and Long-Term Outcome after Myocardial Infarction. Real-World Data from the French FAST-MI 2005 Registry
Authors: Marie-Christine Iliou, Romain Andre, Geraldine Vedrenne, Herve Douard, Marianne Zeller, Alain Furber, Gilles Lemesle, Jean Ferrieres, Tabassome Simon, Nicolas Danchin
Journal: Circulation (2012)

Background and aim: Prospective trials have yielded conflicting results on the survival impact of rehabilitation after AMI. Little is known, however, of the association between use of cardiac rehab...
Health-care utilization and cost for the treatment of melanoma in the six months following diagnosis
Authors: D. C. Taylor, Z. Zhou, S. Haider, D. Thompson
Journal: Journal of Clinical Oncology (2006)

18005 Background: The objective of this study was to use a 5% sample of Medicare claims data to estimate health-care utilization and cost for the treatment of melanoma. Methods: Data for this study were obtained from national administrative Medicare files. Adult patients were selected for the analysis if they were newly diagnosed with melanoma between July 1, 1999 and June 30, 2001. Patients with diagnoses of other cancers prior to melanoma as well as those who did not have data available for at least six months of continuous follow-up were excluded from the analysis. Patients were identified as having Stage 0-II or Stage III-IV melanoma based on the absence or receipt, respectively, of lymph node dissection, chemotherapy, and/or radiation therapy. Study measures included the type, cost, and duration of melanoma treatment. Results: A total of 1,465 patients were identified for the study, including 1,291 with Stage 0-II melanoma and 174 with Stage III-IV melanoma. The mean age was 73.9 years, 54% were female. Overall, 98.3% of patients underwent a surgical procedure, 3.1% underwent chemotherapy, 2.3% had inpatient treatment, 1.2% received radiation, and 1.5% had home health treatment for melanoma in the first six months after diagnosis. Corresponding percentages by disease stage were 100%, 0%, 1.2%, 0%, and 0.9% for Stage 0-II patients, and 85.6%, 25.9%, 10.9%, 10.3%, and 6.3% for Stage III-IV patients. The average total six-month Medicare cost of care was $2,395 ($2,065 outpatient, $330 inpatient) per patient; the average per-patient cost of care was $1,402 ($1,292 outpatient, $110 inpatient) for Stage 0-II patients and was $9,756 ($7,800 outpatient, $1,956 inpatient) for Stage III-IV patients. Conclusions: Treatment costs for melanoma are substantial in the first six months following diagnosis, especially for those patients with Stage III-IV disease. No significant financial relationships to disclose.
Biliary Sludge
Authors: Todd H. Baron
Journal: Annals of Internal Medicine (1999)

Letters19 October 1999Biliary SludgeTodd H. Baron, MDTodd H. Baron, MDMayo Clinic; Rochester, MN 55905 (Baron)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-8-199910190-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I believe that Ko and colleagues (1) omitted endoscopic biliary sphincterotomy as an important treatment option for symptomatic biliary sludge. As mentioned by the authors, factors promoting the formation of biliary sludge include gallbladder dysmotility and biliary constituents. Endoscopic sphincterotomy has been shown to inhibit stone formation in the gallbladder of experimental animals by improving gallbladder emptying. In addition, studies in humans have demonstrated that endoscopic biliary sphincterotomy decreases the stasis of gallbladder bile, as evidenced by a significant reduction of mean gallbladder fasting volume, mean residual volume, and improved gallbladder emptying (2, 3). These changes in ...References1. Ko CW, Sekijima JH, Lee SP. Biliary sludge. Ann Intern Med. 1999;130:301-11. LinkGoogle Scholar2. Sharma BC, Agarwal DK, Baijal SS, Negi TS, Choudhuri G, Saraswat VA. Effect of endoscopic sphincterotomy on gall bladder bile lithogenicity and motility. Gut. 1998;42:288-92. CrossrefMedlineGoogle Scholar3. Dhiman RK, Phanish MK, Chawla YK, Dilawari JB. Gallbladder motility and lithogenicity of bile in patients with choledocholithiasis after endoscopic sphincterotomy. J Hepatol. 1997;26:1300-5. CrossrefMedlineGoogle Scholar4. Sugiyama M, Atomi Y. Longterm effects of endoscopic sphincterotomy on gallbladder motility. Gut. 1996;39:856-9. CrossrefMedlineGoogle Scholar5. Lee SP, Nicholls JF, Park HZ. Biliary sludge as a cause of acute pancreatitis. N Engl J Med. 1992;326:589-93. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic; Rochester, MN 55905 (Baron) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBiliary Sludge Cynthia W. Ko , John H. Sekijima , and Sum P. Lee Biliary Sludge James E. Dill Metrics 19 October 1999Volume 131, Issue 8Page: 630KeywordsAlgorithmsBileCholecystectomyElderlyGallbladderPancreatitisSludge Issue Published: 19 October 1999 CopyrightCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
TP53 codon 72 single nucleotide polymorphism (SNP) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients (p)
Authors: L. Nunez, D. Isla, R. Rosell, M. Taron, A. Artal, I. Bover, V. Alberola, C. Camps, J. J. Sanchez, M. A. Munoz
Journal: Journal of Clinical Oncology (2004)

7161 Background: TP53 occupies a central role in mediating cellular responses to genotoxic insults through its effects on gene transcription and DNA synthesis and repair. The codon 72 SNP in exon 4, carried by 20–40% of the population, leads to an arginine to proline substitution (G-C transversion). We hypothesized that CC homozyogtes and C-carriers (heterozygotes) could have better response and survival Methods: 202 stage IV NSCLC p were included from August 2001 to July 2002. TaqMan 5' nuclease assay was used to examine TP53 72 SNP from baseline peripheral blood lymphocytes. Results:: p characteristics: median age: 61; 91% male; PS 0: 23.4%, 1: 62.7%, 2: 13.9%; adenocarcinoma: 43.1%, pleural effusion: 16%. Overall: response rate (RR) 38.6%; time to progression (TTP) 6 months (m); median survival (MS) 10.56 m. TP53 72 genotypes: GG 60.4%; GC 34.4%; CC 5.2%. By genotype: RR: GG 43%, GC: 38.5%, CC 40%; TTP: GG 6 m, GC 5.8 m, CC 8.7 m; MS: GG 9.8 m, GC 12.3 m, CC 10.5 m. For p with extrapulmonary metastases, those with PS 0 had a lower risk of progression than those with PS 1 (hazard ratio = 0.4; P=0.006); TTP 8.7 m vs 4.4 m (P=0.007). Such differences were not found for p with pulmonary metastases Conclusions: Although TP53 72 SNP was an attractive candidate marker for chemotherapy outcome, our results provide little support for this hypothesis. Intriguingly, among p with good PS, those with extrapulmonary metastases and PS 0 had significantly better outcome than those with PS 1. No significant financial relationships to disclose.
Phase II study of clinical activity of pegaspargase in women with relapsed or refractory epithelial ovarian, fallopian tube, and/or primary peritoneal cancer.
Authors: G. Kim, J. Squires, M. Yu, A. Walker, N. D. Houston, L. Otten, E. C. Kohn
Journal: Journal of Clinical Oncology (2010)

TPS258 Background: Although the bacterial enzyme L-asparaginase (L-ASP) has been used in combination with traditional cytotoxic therapy for decades, its use has been limited mainly to its FDA-approved treatment of acute lymphoblastic leukemia. By catalyzing the hydrolysis of asparagine to aspartate, L-ASP depletes serum levels of asparagine resulting in direct cytotoxicity of sensitive cells. The noncytotoxic effects of L-ASP, such as the inhibition of glycoprotein synthesis, have been known for decades. Our ongoing preclinical work has demonstrated that L-ASP reduces the ability of endothelial cells to form capillary-like tubes, reduces the invasive potential of endothelial cells and cancer cells, and prevents heterotypic interaction between ovarian cancer and endothelial cells. These results suggest that L-ASP may provide therapeutic benefit by inhibiting angiogenesis, invasion and metastasis. Our finding that L-ASP is capable of modifying the tumor microenvironment led us to hypothesize that pegaspargase may be effective as a single agent in providing disease response or stabilization. Methods: Objectives: 1) To evaluate the antitumor activity of pegaspargase, 2,000 IU/ m2 every two weeks IV in patients with recurrent or refractory ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer. 2) To explore pharmacodynamic endpoints such as changes in circulating angiogenic cytokines, signal transduction pathway alterations, and tumor vascularity. Eligibility: Adults with histologically documented recurrent ovarian, fallopian tube, or peritoneal cancer for whom standard curative therapies do not exist or are no longer effective. Design: This is an open-label phase II, and will be conducted as a two- stage trial, in order to evaluate whether a sufficiently high proportion of patients are able to attain a 6 month progression free interval using pegaspargase 2,000 IU/m2 IV q 2 wk. Patients will undergo functional imaging and biopsy or fluid aspiration prior to and at 6 weeks of therapy for translational endpoints. The first stage accrual is 13 patients with an estimated 30 total patients needed to achieve the objectives of this trial. No significant financial relationships to disclose.
Cancer-specific nanotheranostics to improve the diagnosis and treatment of bladder cancer.
Authors: Chong-Xian Pan, Tzu-yin Lin, Hongyong Zhang, Yuanpei Li, Susan D. Airhart, Ralph deVere White, Kit S. Lam
Journal: Journal of Clinical Oncology (2015)

323 Background: We recently developed a bladder cancer-specific targeting ligand named PLZ4, nanometer-scale micelles and nanoporphyrin. Here we report the diagnostic and therapeutic applications of these nanotheranostics coated with PLZ4. Methods: PLZ4 was synthesized through solid phase synthesis. Bladder cancer-specific PLZ4-coated nanomicelles (PNM) and nanoporphyrin (PNP) were developed through conjugating the nanotheranostics with PLZ4 on the surface, and loaded with therapeutic and/or imaging agents in the core. Bladder cancer cell lines and patient-derived xenografts (PDXs) were used to determine the diagnostic and therapeutic applications. Results: In vitro studies with cell lines revealed that both PNM and PNP could specifically deliver the drug load to bladder cancer cells, but not to adjacent confounding cells. After intravenous injection, PNM loaded with paclitaxel could specifically deliver the drug load to xenografts developed from a human and a dog bladder cancer cell line, and a PDX, but not to lung cancer xenografts in the same mice. These paclitaxel-loaded PNM could overcome cisplatin resistance, and prolong the overall survival of mice carrying PDXs from 27 days with free paclitaxel to 76 days (p&lt;0.0001). PNP can be used for photodynamic diagnosis and therapy while being able to chelate gadolinium for cancer-specific magnetic resonance imaging (MRI), and load chemotherapeutic drugs for cancer-specific targeted chemotherapy. It is over 50 times more potent that 5-aminolevulinic acid in photodynamic therapy (p&lt;0.0001). After intravesical instillation into the bladder cavity of an orthotopic PDX model, PNP could specifically target bladder cancer cells, but not adjacent normal urothelial cells in the same bladder. Conclusions: PNM and PNP can potentially be used for diagnosis, imaging detection and cancer-specific targeted delivery of therapeutic agents of both non-myoinvasive and advanced bladder cancer. A phase I clinical trial of PNM for intravesical instillation in human patients with non-myoinvasive bladder cancer, and another phase I trial with PNP for photodynamic diagnosis and therapy in dog bladder cancer patients have been funded.